Does Treatment of Jaundice Matter before Pancreaticoduodenectomy? Results from an International Multicentre Recurrence after Whipple (RAW) Study
European Surgical Research · 20.05.2026 · 67 (1) · 107-116
DOI: 10.1159/000552543 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Surgical Research, online erschienen am 20.05.2026. Verfasst von Bibek Das und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Cancer, Imperial College London, London, UK, bibek.das07@imperial.ac.uk. Hauptthemen laut MEDLINE: Jaundice, Pancreatic Neoplasms, Pancreaticoduodenectomy. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The management of jaundice before pancreaticoduodenectomy (PD) remains controversial. We aimed to analyse the clinical outcomes of jaundiced patients in a large cohort of PD patients stratified by treatment pathway.
Methods
Data were collected from the Recurrence After Whipple’s (RAW) study – an international, multicentre, retrospective cohort study of PD patients. Patients that underwent PD with subsequent histology confirmed pancreatic head ductal adenocarcinoma, ampullary adenocarcinoma, and distal cholangiocarcinoma were included in the RAW study. Patients were stratified into three groups by management of preoperative jaundice.
Results
Patients (n = 1,172) were classified into three groups: surgery while jaundiced (n = 109), surgery after successful preoperative biliary drainage (PBD) (n = 777), and not jaundiced (n = 286). Jaundice was an independent predictor of poor survival, whether treated (HR 1.45, CI 1.20–1.76) or untreated (HR 1.55, CI 1.16–2.09) pre-operatively. On multivariate analysis, PBD was associated with improved disease-free survival (HR 0.75, CI 0.58–0.97) but not overall survival (HR 0.93, CI 0.72–1.20) relative to the untreated jaundiced population. PBD was associated with a reduced, but statistically nonsignificant, risk of PD-related complications (OR 0.63 CI 0.39–1.02; p = 0.059).
Conclusion
We observed a nonsignificant trend towards reduced perioperative complications and improved disease-free survival following PBD prior to PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery and Cancer, Imperial College London, London, UK, bibek.das07@imperial.ac.uk.
- Imperial College Healthcare NHS Trust, London, UK, bibek.das07@imperial.ac.uk.
- Department of Surgery and Cancer, Imperial College London, London, UK.
- Department of Surgery, Maidstone and Tunbridge Well NHS Trust, Kent, UK.
- Imperial College Healthcare NHS Trust, London, UK.
- University Hospitals Plymouth NHS Trust, Plymouth, UK.
Zitieren
APA
Das, B., Robb, H. D., Bobotis, S., Alghazawi, L. O. K., Ashrafian, H., Pai, M., Fehervari, M., Aroori, S., & Spalding, D. (2026). Does Treatment of Jaundice Matter before Pancreaticoduodenectomy? Results from an International Multicentre Recurrence after Whipple (RAW) Study. European Surgical Research, 67(1), 107-116. https://doi.org/10.1159/000552543
Vancouver
Das B, Robb HD, Bobotis S, Alghazawi LOK, Ashrafian H, Pai M, et al. Does Treatment of Jaundice Matter before Pancreaticoduodenectomy? Results from an International Multicentre Recurrence after Whipple (RAW) Study. European Surgical Research. 2026;67(1):107-116. doi:10.1159/000552543
BibTeX
@article{Das2026,
author = {Das, Bibek and Robb, Henry Douglas and Bobotis, Stergios and Alghazawi, Laith Omar Khalaf and Ashrafian, Hutan and Pai, Madhava and Fehervari, Matyas and Aroori, Somaiah and Spalding, Duncan},
title = {Does Treatment of Jaundice Matter before Pancreaticoduodenectomy? Results from an International Multicentre Recurrence after Whipple (RAW) Study},
journal = {European Surgical Research},
year = {2026},
volume = {67},
number = {1},
pages = {107--116},
doi = {10.1159/000552543}
}
EUVIMED